USPTO 2015–2025 USPTO PatentsView US Corporation

Ultima Genomics, Inc.

USPTO PatentsView assignee record — 53 granted patents across 15 technology areas, active 2019–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR).

53
Total patents granted
15
CPC technology areas
22.8
Avg claims per patent
+1125%
5-year filing velocity

The verdict

Ultima holds 53 US patents across 15 technology areas — rank #6,397 of 50,000 tracked assignees.

#6,397
of 50,000 US assignees by volume
Top 3%
by Innovation Score (61.1/100)
22.8
avg claims per patent
+1125%
filing velocity, last 5 yrs

Portfolio overview

Ultima Genomics, Inc. has been granted 53 US utility patents between 2019 and 2025, placing Ultima Genomics, Inc. at rank #6,397 across all assignees tracked by PlainPatent. This portfolio spans 15 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.8 claims per patent with primary concentration in C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICR). As a US Corporation, Ultima Genomics, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 61.1/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 49 grants, compared with 4 in the 2015–2019 window — a +1125% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. Ultima Genomics, Inc.'s 22.8 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 15 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Ultima Genomics, Inc. against peers pursuing similar technology classes.

How does Ultima compare?

Granted US patents 2015–2025 versus the largest corporate holders — this company marked ◀

patents

What this shows Ultima holds 53 patents — placing it at rank #6,397 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.

Source USPTO PatentsView — granted utility patents As of 2015–2025

Ultima's Innovation Score vs. every tracked assignee

Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)

61 Top 3% higher than 97% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). Below this entry. 40–50: 11,491 US assignees (23%). Below this entry. 50–60: 5,058 US assignees (10%). Below this entry. 60–70: 1,537 US assignees (3%). This entry sits in this band. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView — PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2019–2025

051015 2019202020212022202320242025 8
USPTO utility patent grants by year · 2019–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.

View data table
Ultima Genomics, Inc. patent grants by year, 2015–2025
Year Patents Granted Share of Period
2019 4 7.5%
2020 2 3.8%
2021 4 7.5%
2022 14 26.4%
2023 11 20.8%
2024 10 18.9%
2025 8 15.1%

Which technologies does Ultima Genomics, Inc. patent most?

Top 15 of 15 technology areas

Patent Moat Analysis

Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating

Where it ranks

Overall rank by patents

#6,397

Across all tracked assignees

Innovation Score

61.1 out of 100

View all rankings →

Data Source

USPTO PatentsView — US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

How many patents does Ultima Genomics, Inc. hold?
Ultima Genomics, Inc. holds 53 US granted patents filed between 2019 and 2025, spanning 15 technology areas.
What is Ultima Genomics, Inc.'s Innovation Score?
Ultima Genomics, Inc. has an Innovation Score of 61.1 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Ultima Genomics, Inc. focus on?
Ultima Genomics, Inc.'s top technology area is C12Q (MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES) with 44 patents. The company has filed patents in 15 CPC subclasses total.
Is Ultima Genomics, Inc.'s patent filing rate increasing or decreasing?
Ultima Genomics, Inc.'s recent filing velocity is +1125% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Ultima Genomics, Inc.'s patents?
Ultima Genomics, Inc.'s patents average 22.8 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Ultima Genomics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

Learn More

How to use this portfolio

Ultima's 53 grants land it in the top 3% by Innovation Score — but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance — Ultima ranks #6,397 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12Q — see who else leads that technology area. C12Q leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity — not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Explore the patent dataset

Data sourced from USPTO PatentsView — official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Data sources used on this page
  • USPTO PatentsView — the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
  • Cooperative Patent Classification (CPC) — the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
  • USPTO Patent Public Search — the official interface to verify the status of any individual patent. ppubs.uspto.gov